Jump-starting the conversation about harm reduction: making sense of drug effects

References

• Adley, M. (2012). The Drugs Wheel Game. Retrieved 16 December 2020 from http://www.thedrugswheel.com/?page=game
   Google Scholar
• Adley, M, & The Loop (2018). The Club Drugs Wheel. Retrieved 12 December 2020 from http://www.thedrugswheel.com/?page=clubdrugswheel
   Google Scholar
• Alcohol and Drug Foundation (2019). Drug Facts: Drug Wheel. Retrieved 12 December 2020 from https://adf.org.au/drug-facts/#wheel
   Google Scholar
• Basavarajappa, B. S., & Subbanna, S. (2019). Potential mechanisms underlying the deleterious effects of synthetic cannabinoids found in spice/k2 products. Brain Sciences, 9(1), 14. https://doi.org/10.3390/brainsci9010014
   PubMed Web of Science ®Google Scholar
• Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015). Legal highs: staying on top of the flood of novel psychoactive substances. Therapeutic Advances in Psychopharmacology, 5(2), 97–132. https://doi.org/10.1177/2045125314559539
   PubMed Web of Science ®Google Scholar
• Becker, H. S. (1967). History, culture and subjective experience: an exploration of the social bases of drug-induced experiences. Journal of Health and Social Behavior, 8(3), 163–176. https://doi.org/10.2307/2948371
   PubMed Web of Science ®Google Scholar
• Bedi, G., Hyman, D., & de Wit, H. (2010). Is ecstasy an “empathogen”? Effects of ±3, 4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biological Psychiatry, 68(12), 1134–1140. https://doi.org/10.1016/j.biopsych.2010.08.003
   PubMed Web of Science ®Google Scholar
• Bennett, K. H., Hare, H. M., Waller, R. M., Alderson, H. L., & Lawrie, S. (2017). Characteristics of NPS use in patients admitted to acute psychiatric services in Southeast Scotland: a retrospective cross-sectional analysis following public health interventions. BMJ Open, 7(12), e015716. https://doi.org/10.1136/bmjopen-2016-015716
   PubMed Web of Science ®Google Scholar
• Bluelight (2020). Retrieved 12 December 2020 from https://www.bluelight.org/xf/
   Google Scholar
• Bossong, M., Van Dijk, J., & Niesink, R. (2005). Methylone and mCPP, two new drugs of abuse? Addiction Biology, 10(4), 321–323. https://doi.org/10.1080/13556210500350794
   PubMed Web of Science ®Google Scholar
• Box, G. E. P., Luceno, A., & del Carmen Paniagua-Quinones, M. (2011). Statistical control by monitoring and adjustment. (2nd ed., Vol. 700). John Wiley & Sons.
   Google Scholar
• Brandt, S. D., Braithwaite, R. A., Evans-Brown, M., & Kicman, A. T. (2013). Aminoindane Analogues. In P. I. Dargan & D. M. Wood (Eds.), Novel psychoactive substances: classification, pharmacology and toxicology. (pp. 261–283). Academic Press. https://doi.org/10.1016/b978-0-12-415816-0.00011-0
   Google Scholar
• Christiansen, C. (1994). Classification and study in occupation a review and discussion of taxonomies. Journal of Occupational Science, 1(3), 3–20. https://doi.org/10.1080/14427591.1994.9686382
   Google Scholar
• Constance, L. (1957). Plant taxonomy in an age of experiment. American Journal of Botany, 44(1), 88–92. https://doi.org/10.2307/2438350
   Web of Science ®Google Scholar
• Corazza, O., Schifano, F., Simonato, P., Fergus, S., Assi, S., Stair, J., Corkery, J., Trincas, G., Deluca, P., Davey, Z., Blaszko, U., Demetrovics, Z., Moskalewicz, J., Enea, A., Melchiorre, G., Mervo, B., Furia, L., Farre, M., Flesland, L., … Scherbaum, N. (2012). Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Human psychopharmacology, 27(2), 145–149. https://doi.org/10.1002/hup.1242
   PubMed Web of Science ®Google Scholar
• Coulon, P., & Gorji, A. (2016). Tightrope or slackline? The neuroscience of psychoactive substances. Trends in Pharmacological Sciences, 37(7), 511–521. https://doi.org/10.1016/j.tips.2016.04.004
   PubMed Web of Science ®Google Scholar
• Creative Commons (2021). Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International. Retrieved 16 December 2020 from https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode
   Google Scholar
• Davey, Z., Schifano, F., Corazza, O., Deluca, P., & Group, P. W. M, Psychonaut Web Mapping Group (2012). e-Psychonauts: conducting research in online drug forum communities. Journal of Mental Health, 21(4), 386–394. https://doi.org/10.3109/09638237.2012.682265
   PubMed Web of Science ®Google Scholar
• Deluca, P., Davey, Z., Corazza, O., Di Furia, L., Farre, M., Flesland, L. H., Mannonen, M., Majava, A., Peltoniemi, T., Pasinetti, M., Pezzolesi, C., Scherbaum, N., Siemann, H., Skutle, A., Torrens, M., van der Kreeft, P., Iversen, E., & Schifano, F. (2012). Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 39(2), 221–226. https://doi.org/10.1016/j.pnpbp.2012.07.011
   PubMed Web of Science ®Google Scholar
• Díaz, J. L. (1979). Ethnopharmacology and Taxonomy of Mexican Psychodysleptic Plants. Journal of Psychedelic Drugs, 11(1-2), 71–101. https://doi.org/10.1080/02791072.1979.10472094
   PubMed Web of Science ®Google Scholar
• Di Matteo, V., Di Giovanni, G., Pierucci, M., & Esposito, E. (2008). Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Progress in Brain Research, 172, 7–44. https://doi.org/10.1016/s0079-6123(08)00902-3
   PubMed Web of Science ®Google Scholar
• Dondante (2011). (25C-NBOMe/500 µg) First time: Van-Goghian masterpiece. https://www.bluelight.org/xf/threads/25c-nbome-500-%C2%B5g-first-time-van-goghian-masterpiece.564781/
   Google Scholar
• DrugWatchUK (2021). UK and Ireland DrugWatch. Retrieved from December 06, 2021 from https://michaellinnell.org.uk/drugwatch.html
   Google Scholar
• Drug Education Network (2020). Exploring the Drug Wheel. Retrieved 06 February 2021 from https://www.youtube.com/watch?v=ETDuFgZosWw
   Google Scholar
• EMCDDA (2013). EU Drug Markets Report: a strategic analysis. European Monitoring Centre for Drugs and Drug Addiction, Publications Office of the European Union. https://www.emcdda.europa.eu/system/files/publications/741/TD3112366ENC_406102.pdf
   Google Scholar
• EMCDDA (2019a). EU Drug Markets Report 2019. European Monitoring Centre for Drugs and Drug Addiction: Publications Office of the European Union. https://www.emcdda.europa.eu/system/files/publications/12078/20192630_TD0319332ENN_PDF.pdf
   Google Scholar
• EMCDDA (2019b). European Prevention Curriculum: a handbook for decision-makers, opinion-makers and policy-makers in science-based prevention of substance use. European Monitoring Centre for Drugs and Drug Addiction. https://www.emcdda.europa.eu/publications/manuals/european-prevention-curriculum_en
   Google Scholar
• EMCDDA (2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. European Monitoring Centre for Drugs and Drug Addiction: Publications Office of the European Union. https://www.emcdda.europa.eu/system/files/publications/13464/20205648_TD0320796ENN_PDF_rev.pdf
   Google Scholar
• EMCDDA (2021). European drug report 2021: Trends and developments. European Monitoring Centre for Drugs and Drug Addiction: Publications Office of the European Union. https://www.emcdda.europa.eu/system/files/publications/13838/TDAT21001ENN.pdf
   Google Scholar
• Fantegrossi, W. E., Wilson, C. D., & Berquist, M. D. (2018). Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metabolism Reviews, 50(1), 65–73. https://doi.org/10.1080/03602532.2018.1428343
   PubMed Web of Science ®Google Scholar
• Fink, M. (1980). An objective classification of psychoactive drugs. Progress in Neuro-Psychopharmacology, 4(4-5), 495–502. https://doi.org/10.1016/0364-7722(80)90019-3
   PubMedGoogle Scholar
• Fletcher, E. H., Tasker, S. M., Easton, P., & Denvir, L. (2016). Improving the help and support provided to people who take new psychoactive substances ('legal highs')). Journal of Public Health (Oxford, England), 38(4), e489–e495. https://doi.org/10.1093/pubmed/fdv191
   PubMed Web of Science ®Google Scholar
• Gilani, F. (2015). Legal highs’: Novel psychoactive substances. InnovAiT: Education and Inspiration for General Practice, 8(12), 717–724. https://doi.org/10.1177/1755738015612509
   Google Scholar
• Gilmour, J. S., & Walters, S. M. (1964). Philosophy and Classification. In W. B. Turrill (Ed.), Vistas in Botany. (pp. 1–22). Pergamon Press.
   Google Scholar
• Hearne, E., & Van Hout, M. C. (2016). "Trip-Sitting" in the black hole: a netnographic study of dissociation and indigenous harm reduction. Journal of Psychoactive Drugs, 48(4), 233–242. https://doi.org/10.1080/02791072.2016.1207827
   PubMed Web of Science ®Google Scholar
• Herrling, P. L., Emre, M., & Watkins, J. (1997). D-CPPene (SDZ EAA-494)—a competitive NMDA antagonist: pharmacology and results in humans. In P. L. Herrling (Ed.), Excitatory Amino Acids. (pp. 7–21). Academic Press.
   Google Scholar
• Home Office (2015). New Psychoactive Substances (NPS) Resource Pack for informal educators and practitioners. https://www.gov.uk/government/publications/new-psychoactive-substances-nps-resource-pack
   Google Scholar
• Home Office (2018). Review of the Psychoactive Substances Act 2016. Crown Copyright. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/756902/Review_of_the_Psychoactive_Substances_Act__2016___print_-_content_.pdf
   Google Scholar
• Jacobsen, E. (1959). The comparative pharmacology of some psychotropic drugs. Bulletin of the World Health Organization, 21(4-5), 411–493.
   PubMedGoogle Scholar
• Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management, 39(2), 167–179. https://doi.org/10.1016/j.jpainsymman.2009.06.008
   PubMed Web of Science ®Google Scholar
• Julien, R. M., Advokat, C. D., & Comaty, J. E. (2011). A Primer of Drug Action: A comprehensive guide to the actions, uses, and side effects of psychoactive drugs, revised and updated. (12 ed.). Worth.
   Google Scholar
• Jünger, E. (1970). Annäherungen: Drogen und Rausch. Klett-Cotta. https://libcom.org/files/Approaches%20-%20Drugs%20and%20Ecstatic%20Intoxication%20-%20Ernst%20Junger_1.pdf
   Google Scholar
• King, L. A. (2013). Novel psychoactive substances classification, pharmacology and toxicology. In P. I. Dargan & D. M. Wood (Eds.), Novel psychoactive substances: classification, pharmacology and toxicology. Academic Press.
   Google Scholar
• Leonard, B. E. (2010). Classification of psychoactive drugs. In I. Stolerman (Ed.), Encyclopedia of Psychopharmacology. (pp. 293–302). Springer.
   Google Scholar
• Lewin, L. (1924). Phantastica: Die betaubenden und erregenden Genussmittel. Georg Stilke. https://publikationsserver.tu-braunschweig.de/receive/dbbs_mods_00036941
   Google Scholar
• Liechti, M. E. (2015). Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Medical Weekly, 145, w14043. https://doi.org/10.4414/smw.2015.14043
   PubMed Web of Science ®Google Scholar
• Lingford-Hughes, A. (2004). Drugs of abuse. In I. M. Anderson & I. C. Reid (Eds.), Fundamentals of Clinical Psychopharmacology. (2nd ed., pp. 114–127). Taylor & Francis.
   Google Scholar
• Macdonald, I. (2019). Teen Substance Use, Mental Health and Body Image: Practical Strategies for Support. Jessica Kingsley Publishers.
   Google Scholar
• MacLeod, K., Pickering, L., Gannon, M., Greenwood, S., Liddel, L, Smith, A., Johnstone, L., & Burton, G. (2016). Understanding the patterns of use, motives, and harms of new psychoactive substances in Scotland. Final report to the Scottish Government. https://www.gov.scot/publications/understanding-patterns-use-motives-harms-new-psychoactive-substances-scotland/
   Google Scholar
• Maier, J., Mayer, F. P., Luethi, D., Holy, M., Jäntsch, K., Reither, H., Hirtler, L., Hoener, M. C., Liechti, M. E., Pifl, C., Brandt, S. D., & Sitte, H. H. (2018). The psychostimulant (±)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. Neuropharmacology, 138, 282–291. https://doi.org/10.1016/j.neuropharm.2018.06.018
   PubMed Web of Science ®Google Scholar
• Marwick, K. (2019). Crash Course Psychiatry. (5th ed.). Elsevier.
   Google Scholar
• McCandless, D. (2010). Drugs World. Retrieved 30 May 2021 from https://www.informationisbeautiful.net/visualizations/drugs-world/
   Google Scholar
• McHound (2009). 5-MEO-DALT. https://drugs-forum.com/threads/5-meo-dalt-experiences.40544/page-4#post-904818
   Google Scholar
• McKelvey, B. (1978). Organizational systematics: Taxonomic lessons from biology. Management Science, 24(13), 1428–1440. https://doi.org/10.1287/mnsc.24.13.1428
   Web of Science ®Google Scholar
• Measham, F. (2019). Drug safety testing, disposals and dealing in an English field: Exploring the operational and behavioural outcomes of the UK's first onsite 'drug checking' service. The International Journal on Drug Policy, 67, 102–107. https://doi.org/10.1016/j.drugpo.2018.11.001
   PubMed Web of Science ®Google Scholar
• Measham, F. (2020a). City checking: Piloting the UK's first community-based drug safety testing (drug checking) service in 2 city centres. British Journal of Clinical Pharmacology, 86(3), 420–428. https://doi.org/10.1111/bcp.14231
   PubMed Web of Science ®Google Scholar
• Measham, F. (2020b). The NPS imposters, merging and emerging drug markets and the contribution of drug checking. In D. Bewley-Taylor & K. Tinasti (Eds.), Research Handbook on International Drug Policy. (pp. 341–354). Edward Elgar Publishing.
   Google Scholar
• Measham, F. (2021). Social issues in the use of novel psychoactive substances: differentiated demand, displacement and adulteration. In P. Dargan & D. Wood (Eds.), Novel Psychoactive Substances: Classification, Pharmacology and Toxicology. (2nd ed., pp. 105–127). Elsevier.
   Google Scholar
• Measham, F., & Newcombe, R. (2016). What's so 'new' about new psychoactive substances? Definitions, prevalence, motivations, user groups and a proposed new taxonomy. In T. Kolind, B. Thom, & G. Hunt (Eds.), The SAGE handbook of drug alcohol studies - social science approaches. (pp. 576–596). SAGE Publications Ltd. https://doi.org/10.4135/9781473921986.n33
   Google Scholar
• Measham, F., & Turnbull, G. (2021). Intentions, actions and outcomes: A follow up survey on harm reduction practices after using an English festival drug checking service. The International Journal on Drug Policy, 95, 103270. https://doi.org/10.1016/j.drugpo.2021.103270
   PubMed Web of Science ®Google Scholar
• Mercier, C. A. (1912). A new logic. Open Court Publishing Company.
   Google Scholar
• Mindspelunker (2011). Into the M-Hole. https://www.erowid.org/experiences/exp.php?ID=90865
   Google Scholar
• Möller, I., Wintermeyer, A., Bender, K., Jübner, M., Thomas, A., Krug, O., Schänzer, W., & Thevis, M. (2011). Screening for the synthetic cannabinoid JWH‐018 and its major metabolites in human doping controls. Drug Testing and Analysis, 3(9), 609–620. https://doi.org/10.1002/dta.158
   PubMed Web of Science ®Google Scholar
• Moore, K., & Measham, F. (2011). Impermissible pleasures in UK leisure: Exploring policy developments in alcohol and illicit drugs. In C. Jones, E. Barclay, & R. Mawby (Eds.), The Problem of Pleasure: Leisure, Tourism and Crime. (pp. 62–76). Willan.
   Google Scholar
• Morean, M. E., de Wit, H., King, A. C., Sofuoglu, M., Rueger, S. Y., & O'Malley, S. S. (2013). The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology, 227(1), 177–192. https://doi.org/10.1007/s00213-012-2954-z
   PubMed Web of Science ®Google Scholar
• Morgan, C. J., Muetzelfeldt, L., & Curran, H. V. (2010). Consequences of chronic ketamine self‐administration upon neurocognitive function and psychological wellbeing: a 1‐year longitudinal study. Addiction (Abingdon, England), 105(1), 121–133. https://doi.org/10.1111/j.1360-0443.2009.02761.x
   PubMed Web of Science ®Google Scholar
• Newcombe, R. (1987). High time for harm reduction. Druglink, 2(1), 10.
   Google Scholar
• Newcombe, R. (1999). Psychonautics: A model and method for exploring the subjective effects of psychoactive drugs. Club Health 2000 – First International Conference on Nightlife and Substance Use. https://www.researchgate.net/publication/268576819_Psychonautics_a_model_and_method_for_exploring_the_subjective_effects_of_psychoactive_drugs
   Google Scholar
• Páleníček, T., Lhotková, E., Žídková, M., Balíková, M., Kuchař, M., Himl, M., Mikšátková, P., Čegan, M., Valeš, K., Tylš, F., & Horsley, R. R. (2016). Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 69, 49–59. https://doi.org/10.1016/j.pnpbp.2016.04.004
   PubMed Web of Science ®Google Scholar
• Parrott, A. C. (2002). Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacology Biochemistry and Behavior, 71(4), 837–844. https://doi.org/10.1016/S0091-3057(01)00711-0
   PubMed Web of Science ®Google Scholar
• Pates, R., & Riley, D. M. (2012). Harm reduction in substance use and high-risk behaviour international policy and practice. Wiley-Blackwell.
   Google Scholar
• Potter, G. R., & Chatwin, C. (2018). Not particularly special: critiquing ‘NPS’ as a category of drugs. Drugs: Education, Prevention and Policy, 25(4), 329–336. https://doi.org/10.1080/09687637.2017.1411885
   Web of Science ®Google Scholar
• Ruane, D. (2018). Field experiments: psychonauts' efforts to reduce the harm of old and new drugs at music festivals. Drugs: Education, Prevention and Policy, 25(4), 337–344. https://doi.org/10.1080/09687637.2017.1418836
   Web of Science ®Google Scholar
• Sáez-Briones, P., & Hernández, A. (2013). MDMA (3, 4-methylenedioxymethamphetamine) analogues as tools to characterize MDMA-like effects: an approach to understand entactogen pharmacology. Current Neuropharmacology, 11(5), 521–534. https://doi.org/10.2174/1570159X11311050007
   PubMed Web of Science ®Google Scholar
• Sahai, M., Davidson, C., Dutta, N., & Opacka-Juffry, J. (2018). Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS) and Their Discrimination by the Dopamine Transporter—In Silico and In Vitro Exploration of Dissociative Diarylethylamines. Brain Sciences, 8(4), 63. https://doi.org/10.3390/brainsci8040063
   PubMed Web of Science ®Google Scholar
• Sainsbury, P., Kicman, A., Archer, R., King, L., & Braithwaite, R. (2011). Aminoindanes—the next wave of ‘legal highs’? Drug Testing and Analysis, 3(7-8), 479–482. https://doi.org/10.1002/dta.318
   PubMed Web of Science ®Google Scholar
• Sammut, D., & Craig, C. (2019). Bitter pill: Testing times for party drugs. Chemistry in Australia.
   Google Scholar
• Schifano, F., Albanese, A., Fergus, S., Stair, J. L., Deluca, P., Corazza, O., Davey, Z., Corkery, J., Siemann, H., Scherbaum, N., Farre', M., Torrens, M., Demetrovics, Z., & Ghodse, A. H., ReDNet Research Groups (2011). Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology, 214(3), 593–602. https://doi.org/10.1007/s00213-010-2070-x
   PubMed Web of Science ®Google Scholar
• Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2019). New Psychoactive Substances (NPS), psychedelic experiences and dissociation: clinical and clinical pharmacological issues. Current Addiction Reports, 6(2), 140–152. https://doi.org/10.1007/s40429-019-00249-z
   Google Scholar
• Scotton, W. J., Hill, L. J., Williams, A. C., & Barnes, N. M. (2019). Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. International Journal of Tryptophan Research : IJTR, 12, 1178646919873925. https://doi.org/10.1177/1178646919873925
   Web of Science ®Google Scholar
• Seifert, R., & Schirmer, B. (2020). A simple mechanistic terminology of psychoactive drugs: a proposal. Naunyn-Schmiedeberg's Archives of Pharmacology, 393(8):1331–1339. https://doi.org/10.1007/s00210-020-01918-x
   PubMed Web of Science ®Google Scholar
• Shulgin, A., & Shulgin, A. (1991). PIKHAL: A Chemical Love Story. Transform Press.
   Google Scholar
• Simmler, L. D., & Liechti, M. E. (2018). Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances. In H. Maurer & S. Brandt (Eds.), New Psychoactive Substances. Handbook of Experimental Pharmacology. (Vol. 252, pp. 143–164). Springer International Publishing. https://doi.org/10.1007/164_2018_113
   Google Scholar
• Soussan, C., & Kjellgren, A. (2014). Harm reduction and knowledge exchange-a qualitative analysis of drug-related Internet discussion forums. Harm Reduct J, 11(1), 25–25. https://doi.org/10.1186/1477-7517-11-25
   PubMed Web of Science ®Google Scholar
• Stevens, A., & Measham, F. (2014). The ‘drug policy ratchet’: why do sanctions for new psychoactive drugs typically only go up? Addiction, 109(8), 1226–1232. https://doi.org/10.1111/add.12406
   PubMed Web of Science ®Google Scholar
• Stolerman, I. (Ed.) (2010). Encyclopedia of psychopharmacology. Berlin: Springer Science & Business Media.
   Google Scholar
• Sumnall, H. R., Cole, J. C., & Jerome, L. (2006). The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. Journal of Psychopharmacology (Oxford, England), 20(5), 670–682. https://doi.org/10.1177/0269881106060764
   PubMed Web of Science ®Google Scholar
• UNODC (2013). The challenge of new psychoactive substances: a Report from the Global SMART Programme. https://www.unodc.org/unodc/en/scientists/the-challenge-of-new-psychoactive-substances–-global-smart-programme.html
   Google Scholar
• Van Hout, M. C., & Brennan, R. (2011). Heads held high’: an exploratory study of legal highs in pre-legislation Ireland. Journal of Ethnicity in Substance Abuse, 10(3), 256–272. https://doi.org/10.1080/15332640.2011.600210
   PubMedGoogle Scholar
• Zinberg, N. E. (1984). Drug set and setting: the basis for controlled intoxicant use. Yale University Art Gallery.
   Google Scholar
• Zohar, J., Nutt, D. J., Kupfer, D. J., Moller, H.-J., Yamawaki, S., Spedding, M., & Stahl, S. M. (2014). A proposal for an updated neuropsychopharmacological nomenclature. European Neuropsychopharmacology : The Journal of the European College of Neuropsychopharmacology, 24(7), 1005–1014. https://doi.org/10.1016/j.euroneuro.2013.08.004
   PubMed Web of Science ®Google Scholar